These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2504600)

  • 1. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
    Cappelletty DM; Rybak MJ
    Antimicrob Agents Chemother; 1996 May; 40(5):1148-52. PubMed ID: 8723456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable in vitro activity of cefaclor, cephalothin and cefadroxil against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Larsson P; Lincoln K; Lind L; Sandberg T
    Scand J Infect Dis; 1988; 20(4):421-4. PubMed ID: 3057617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.
    Finegold SM; Ingram-Drake L; Gee R; Reinhardt J; Edelstein MA; MacDonald K; Wexler H
    Antimicrob Agents Chemother; 1987 Mar; 31(3):443-6. PubMed ID: 3579262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of cefaclor (author's transl)].
    Knothe H
    Infection; 1979; 7 Suppl 6():518-26. PubMed ID: 45087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
    Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
    Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Diagn Microbiol Infect Dis; 1986 Jul; 5(2):151-62. PubMed ID: 3522088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance of gram-negative bacteria against cefaclor and other antibiotics (author's transl)].
    Schassan HH
    Infection; 1979; 7 Suppl 6():527-31. PubMed ID: 399243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of the new oral cephalosporin cefixime.
    Counts GW; Baugher LK; Ulness BK; Hamilton DJ
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):428-31. PubMed ID: 3137053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro comparative bactericidal effect of cefotaxime and cefixime in a kinetic model].
    Rolin O; Roche G; Bouanchaud DH
    Presse Med; 1989 Oct; 18(32):1569-71. PubMed ID: 2530534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
    Nix DE; Symonds WT; Hyatt JM; Wilton JH; Teal MA; Reidenberg P; Affrime MB
    Pharmacotherapy; 1997; 17(1):121-5. PubMed ID: 9017772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of cefixime, cefaclor and loracarbef against urinary pathogens.
    Hamilton-Miller JM; Brumfitt W
    Drugs Exp Clin Res; 1991; 17(10-11):517-9. PubMed ID: 1841042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third generation oral cephalosporins: comparative in vitro kinetics.
    Speciale A; Blandino G; Nicoletti G
    J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potencies of ceftriaxone and cefotaxime in a single chamber pharmacokinetic system simulating their in vivo half-lives.
    Unowsky J; Sattler J; Patel IH
    Chemotherapy; 1989; 35(5):338-44. PubMed ID: 2676404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of cefaclor and cefixime on nasopharyngeal pathogens in children].
    Tomiyama M
    Nihon Jibiinkoka Gakkai Kaiho; 1995 Apr; 98(4):659-68. PubMed ID: 7782974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antibacterial efficacy of cefaclor against bacteria resistant to ampicillin, tetracycline and co-trimoxazole (author's transl)].
    Machka K
    Infection; 1979; 7 Suppl 6():536-9. PubMed ID: 399244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bactericidal activity of amoxicillin and cefaclor in an "in vitro" kinetic model (author's transl)].
    Pothier P; Kazmierczak A; Siebor E; Gaillard MC; Pechinot A
    Ann Microbiol (Paris); 1981; 132(3):293-306. PubMed ID: 7027869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
    Brogden RN; Campoli-Richards DM
    Drugs; 1989 Oct; 38(4):524-50. PubMed ID: 2684593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.